By Associate Professor Anthony Michael Joshua

Journal articles

Pra AD; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; Van Der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG, 2013, 'TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: Implications for fusion status anddsb repair', Clinical Cancer Research, 19, pp. 5202 - 5209, http://dx.doi.org/10.1158/1078-0432.CCR-13-1049

Leibowitz-Amit R; Joshua AM, 2013, 'The changing landscape in metastatic castration-resistant prostate cancer', Current Opinion in Supportive and Palliative Care, 7, pp. 243 - 248, http://dx.doi.org/10.1097/SPC.0b013e328362ffef

Hamid O; Robert C; Daud A; Hodi FS; Hwu WJ; Kefford R; Wolchok JD; Hersey P; Joseph RW; Weber JS; Dronca R; Gangadhar TC; Patnaik A; Zarour H; Joshua AM; Gergich K; Elassaiss-Schaap J; Algazi A; Mateus C; Boasberg P; Tumeh PC; Chmielowski B; Ebbinghaus SW; Li XN; Kang SP; Ribas A, 2013, 'Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma', New England Journal of Medicine, 369, pp. 134 - 144, http://dx.doi.org/10.1056/NEJMoa1305133

Carvajal RD; Sosman JA; Quevedo F; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski T; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Paucar D; Panageas KS; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK, 2013, 'Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).', Journal of Clinical Oncology, 31, pp. CRA9003 - CRA9003, http://dx.doi.org/10.1200/jco.2013.31.18_suppl.cra9003

Manokumar T; Aziz S; Rizvi F; Breunis H; Joshua AM; Tannock I; Alibhai SMH, 2013, 'A prospective study examining PROs and other geriatric outcomes in older adults with prostate cancer undergoing chemotherapy.', Journal of Clinical Oncology, 31, pp. 9555 - 9555, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9555

Ribas A; Robert C; Daud A; Hodi FS; Wolchok JD; Kefford R; Patnaik A; Hwu W-J; Weber JS; Joshua A; Hersey P; Gangadhar TC; Joseph RW; Dronca RS; Zarour HM; Ebbinghaus S; Gergich K; Li XN; Kang SP; Hamid O, 2013, 'Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma.', Journal of Clinical Oncology, 31, pp. 9009 - 9009, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9009

Joshua AM; Zannella VE; Downes MR; Bowes B; Koritzinsky M; Sweet J; Trachtenberg J; Jewett MAS; Finelli A; Fleshner NE; Pollak MN, 2013, 'Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma.', Journal of Clinical Oncology, 31, pp. 5070 - 5070, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5070

Margel D; Urbach DR; Lipscombe L; Bell C; Kilkarni G; Austin P; Joshua AM; Fleshner NE, 2013, 'Metformin use and all-cause and prostate-cancer-specific mortality among diabetic men.', Journal of Clinical Oncology, 31, pp. 5007 - 5007, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5007

Hotte SJ; Eisenhauer EA; Joshua AM; Kumar V; Ellard S; Gregg RW; Macfarlane RJ; Winquist E; Torri V; Ruether JD; Basappa NS; Kakumanu AS; North SA; Kollmannsberger CK; Tinker A; Mirchandani D; Tassignon A; Hausman DF; Allan AL; Chi KN, 2013, 'NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).', Journal of Clinical Oncology, 31, pp. 5042 - 5042, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5042

Leibowitz-Amit R; Templeton AJ; Atenafu EG; Vera-Badillo FE; Chllamma M; Solow HL; Knox JJ; Tannock I; Sridhar SS; Joshua AM, 2013, 'Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC).', Journal of Clinical Oncology, 31, pp. 5058 - 5058, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5058

Carvajal RD; Sosman JA; Quevedo F; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski T; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Paucar D; Panageas KS; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK, 2013, 'Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).', Journal of Clinical Oncology, 31, pp. CRA9003 - CRA9003, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.cra9003

Authors V, 2013, 'Abstracts from the 33rd Annual Scientific Meeting of the Canadian Geriatrics Society Toronto, April 2013', Canadian Geriatrics Journal, 16, pp. 66 - 103, http://dx.doi.org/10.5770/cgj.16.85

Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ, 2013, 'PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade', Modern Pathology, 26, pp. 435 - 447, http://dx.doi.org/10.1038/modpathol.2012.162

Niraula S; Pond G; de Wit R; Eisenberger M; Tannock IF; Joshua AM, 2013, 'Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study', Journal of the Canadian Urological Association, 7, http://dx.doi.org/10.5489/cuaj.267

Templeton AJ; Vera-Badillo FE; Wang L; Attalla M; De Gouveia P; Leibowitz-Amit R; Knox JJ; Moore M; Sridhar SS; Joshua AM; Pond GR; Amir E; Tannock IF, 2013, 'Translating clinical trials to clinical practice: Outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials', Annals of Oncology, 24, pp. 2972 - 2977, http://dx.doi.org/10.1093/annonc/mdt397

Lun G; Atenafu EG; Knox JJ; Sridhar SS; Tannock IF; Joshua AM, 2013, 'Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medication: A pilot project at a canadian cancer center', Clinical Genitourinary Cancer, 11, http://dx.doi.org/10.1016/j.clgc.2013.04.008

Ryan C; Smith M; de Bono J; Molina A; Logothetis D; De Souza P; et A, 2013, 'Abiraterone in metastatic prostate cancer without previous chemotherapy', New England Journal of Medicine, 368, pp. 138 - 148, http://dx.doi.org/10.1056/NEJMoa1209096

Nguyen LT; Butler MO; Yen PH; Nie J; Pniak M; Elford AR; Joshua AM; Hogg D; Ghazarian D; Al-Habeeb A; Easson AM; Leong WL; McCready DR; Reedijk M; Messner HA; Ohashi PS, 2013, 'Development of an adoptive cell therapy protocol with tumor-infiltrating lymphocytes and intermediate-dose interleukin-2 therapy', Journal for immunotherapy of cancer, 1, pp. P25 - P25, http://dx.doi.org/10.1186/2051-1426-1-s1-p25

Alibhai S; Manokumar T; Aziz S; Rizvi F; Breunis H; Gulamhusein H; Timilshina N; Tannock I; Joshua A, 2013, 'Does the hurria/CARG tool or VES-13 predict grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer?', Journal of Geriatric Oncology, 4, pp. S37 - S37, http://dx.doi.org/10.1016/j.jgo.2013.09.031

Leibowitz-Amit R; Templeton A; Alibhai S; Tannock I; Joshua AM, 2013, 'Treatment of octogenarians with castration-resistant prostatecancer with abiraterone and docetaxel', Journal of Geriatric Oncology, 4, pp. S34 - S34, http://dx.doi.org/10.1016/j.jgo.2013.09.025

Scher HI; Fizazi K; Saad F; Taplin M-E; Sternberg CN; Miller K; de Wit R; Mulders P; Chi KN; Shore ND; Armstrong AJ; Flaig TW; Flechon A; Mainwaring P; Fleming M; Hainsworth JD; Hirmand M; Selby B; Seely L; de Bono JS, 2012, 'Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy', NEW ENGLAND JOURNAL OF MEDICINE, 367, pp. 1187 - 1197, http://dx.doi.org/10.1056/NEJMoa1207506

Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM, 2012, 'Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers', BJU International, 110, pp. 840 - 845, http://dx.doi.org/10.1111/j.1464-410X.2011.10922.x

Leibowitz–amit R; Joshua AM, 2012, 'Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions', Current Oncology, 19, pp. 22 - 31, http://dx.doi.org/10.3747/co.19.1281

Joshua AM; Evren S; Zannella VE; Bowes B; Fleshner NE; Jewett MAS; Finelli A; Evans A; Koritzinsky M; Sweet J; Pollak MN, 2012, 'A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.', Journal of Clinical Oncology, 30, pp. e15118 - e15118, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15118

Chi KN; Hotte SJ; Ellard S; Gingerich JR; Joshua AM; Yu EY; Gleave ME, 2012, 'A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC).', Journal of Clinical Oncology, 30, pp. 4514 - 4514, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4514

Montgomery RB; Joshua A; Hannah AL; Peterson AC; Lopez C; Gleave ME; Taplin M-E, 2012, 'A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer.', Journal of Clinical Oncology, 30, pp. TPS4695 - TPS4695, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps4695

Niraula S; Chi K; Joshua AM, 2012, 'Beyond Castration-Defining Future Directions in the Hormonal Treatment of Prostate Cancer', Hormones and Cancer, 3, pp. 3 - 13, http://dx.doi.org/10.1007/s12672-011-0096-0

Fraser M; Zhao H; Luoto KR; Lundin C; Coackley C; Chan N; Joshua AM; Bismar TA; Evans A; Helleday T; Bristow RG, 2012, 'PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: Implications for radiotherapy and chemotherapy', Clinical Cancer Research, 18, pp. 1015 - 1027, http://dx.doi.org/10.1158/1078-0432.CCR-11-2189

Joshua AM; Fleshner N; Pollak M; Zannella V; Bowes B; Koritzinsky M; Sweet J; Evans A; Trachtenberg J; Jewett M; Finelli A, 2012, 'Abstract A15: A phase 2 study of neoadjuvant metformin in prostatic carcinoma', Cancer Research, 72, pp. A15 - A15, http://dx.doi.org/10.1158/1538-7445.prca2012-a15

Morin E; Mete O; Wasserman JD; Joshua AM; Asa SL; Ezzat S, 2012, 'Carney complex with adrenal cortical carcinoma', Journal of Clinical Endocrinology and Metabolism, 97, http://dx.doi.org/10.1210/jc.2011-2321

Joshua AM, 2012, 'Melanoma prevention: Are we doing enough? A Canadian perspective', Current Oncology, 19, http://dx.doi.org/10.3747/co.19.1222

Chi K; Yu EY; Ellard S; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME, 2012, 'A Randomized Phase II Study of OGX-427 Plus Prednisone (P) Vs. P Alone in Patients (PTS) with Metastatic Castration Resistant Prostate Cancer (CRPC)', Annals of Oncology, 23, pp. ix297 - ix297, http://dx.doi.org/10.1016/s0923-7534(20)33525-0

Joshua AM; Shen E; Yoshimoto M; Marrano P; Zielenska M; Evans AJ; Van Der Kwast T; Squire JA, 2011, 'Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies', Prostate, 71, pp. 778 - 790, http://dx.doi.org/10.1002/pros.21294

Squire JA; Park PC; Yoshimoto M; Alami J; Williams JL; Evans A; Joshua AM, 2011, 'Prostate Cancer as a Model System for Genetic Diversity in Tumors', , 112, pp. 183 - 216, http://dx.doi.org/10.1016/B978-0-12-387688-1.00007-7

Joshua A; Evans A; Squire J; Yoshimoto M; Ludkovski O; Tan S-H; Dobi A; Furusato B; Petrovics G; Srivastava S; Sesterhenn I, 2011, '133 EVALUATION OF PTEN AND TMPRSS2-ERG ABNORMALITIES IN PROSTATE CANCER BY FISH AND IMMUNOHISTOCHEMISTRY TO ADDRESS INTRA- AND INTER- TISSUE HETEROGENEITY AND DISEASE PROGRESSION', Journal of Urology, 185, http://dx.doi.org/10.1016/j.juro.2011.02.200

Nguyen LT; Yen PH; Nie J; Liadis N; Ghazarian D; Al-Habeeb A; Easson A; Leong W; Lipa J; McCready D; Reedijk M; Hogg D; Joshua AM; Quirt I; Messner H; Shaw P; Crump M; Sharon E; Ohashi PS, 2010, 'Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)', PLoS ONE, 5, http://dx.doi.org/10.1371/journal.pone.0013940

Chung C; Dawson LA; Joshua AM; Brade AM, 2010, 'Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: Sunitinib and sorafenib', Anti-Cancer Drugs, 21, pp. 206 - 209, http://dx.doi.org/10.1097/CAD.0b013e328333d679

Sahi C; Knox JJ; Clemons M; Joshua AM; Broom R, 2010, 'Renal cell carcinoma bone metastases: Clinical advances', Therapeutic Advances in Medical Oncology, 2, pp. 75 - 83, http://dx.doi.org/10.1177/1758834009358417

Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB, 2009, 'Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer', Journal of Clinical Oncology, 27, pp. 6229 - 6236, http://dx.doi.org/10.1200/JCO.2009.22.3370

Joshua AM; Marrano P; Evans A; Van der Kwast T; Zielenska M; Squire J, 2009, 'Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies', Journal of Clinical Oncology, 27, pp. 11107 - 11107, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.11107

Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ, 2009, 'Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma', Journal of Clinical Endocrinology and Metabolism, 94, pp. 5 - 9, http://dx.doi.org/10.1210/jc.2008-1836

Joshua AM; Evans A; Van der Kwast T; Zielenska M; Meeker AK; Chinnaiyan A; Squire JA, 2008, 'Prostatic preneoplasia and beyond', Biochimica et Biophysica Acta - Reviews on Cancer, 1785, pp. 156 - 181, http://dx.doi.org/10.1016/j.bbcan.2007.12.001

Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA, 2008, 'Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome', Modern Pathology, 21, pp. 1451 - 1460, http://dx.doi.org/10.1038/modpathol.2008.96

Joshua AM; Boutros PC, 2008, 'Web-based resources for clinical bioinformatics.', Methods in molecular medicine, 141, pp. 309 - 329, http://dx.doi.org/10.1007/978-1-60327-148-6_17

Joshua AM; Vukovic B; Braude I; Hussein S; Zielenska M; Srigley J; Evans A; Squire JA, 2007, 'Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer', Neoplasia, 9, pp. 81 - 89, http://dx.doi.org/10.1593/neo.06745

Joshua A; Vukovic B; Braude I; Fleshner NE; Hussein S; Srigley J; Evans A; Zielenska M; Squire J, 2007, '654: Telomere Length Analysis of High-Grade Prostatic Intrapeithelial Neoplasia and Surrounding Stroma Predicts Outcome to Prostate Cancer', Journal of Urology, 177, pp. 220 - 220, http://dx.doi.org/10.1016/s0022-5347(18)30894-2

Dalla-Torre CA; Yoshimoto M; Lee CH; Joshua AM; de Toledo SRC; Petrilli AS; Andrade JAD; Chilton-MacNeill S; Zielenska M; Squire JA, 2006, 'Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma', BMC Cancer, 6, http://dx.doi.org/10.1186/1471-2407-6-237

Yoshimoto M; Cutz JC; Nuin PAS; Joshua AM; Bayani J; Evans AJ; Zielenska M; Squire JA, 2006, 'Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias', Cancer Genetics and Cytogenetics, 169, pp. 128 - 137, http://dx.doi.org/10.1016/j.cancergencyto.2006.04.003

Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Prasad M; Fleshner N; Finelli A; Evans A; Sweet J; Squire J; Zielenska M, 2006, 'Detection of novel variant TMPRSS2 /ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer', Journal of Clinical Oncology, 24, pp. 10029 - 10029, http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10029

Joshua AM; Vukovic B; Braude I; Evans A; Srigley J; Squire JA, 2006, 'Telomere dysfunction in prostatic carcinogenesis', Journal of Clinical Oncology, 24, pp. 10021 - 10021, http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10021

Back to profile page